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Abstract
Background: Computational methods for T cell-based vaccine target discovery focus on selection of highly
conserved peptides identified across pathogen variants, followed by prediction of their binding of human
leukocyte antigen molecules. However, experimental studies have shown that T cells often target diverse regions in
highly variable viral pathogens and this diversity may need to be addressed through redefinition of suitable
peptide targets.
Methods: We have developed a method for antigen assessment and target selection for polyvalent vaccines, with
which we identified immune epitopes from variable regions, where all variants bind HLA. These regions, although
variable, can thus be considered stable in terms of HLA binding and represent valuable vaccine targets.
Results: We applied this method to predict CD8+ T-cell targets in influenza A H7N9 hemagglutinin and
significantly increased the number of potential vaccine targets compared to the number of targets discovered
using the traditional approach where low-frequency peptides are excluded.
Conclusions: We developed a webserver with an intuitive visualization scheme for summarizing the T cell-based
antigenic potential of any given protein or proteome using human leukocyte antigen binding predictions and
made a web-accessible software implementation freely available at http://met-hilab.cbs.dtu.dk/blockcons/.
Background
Along with sanitation, vaccines are the most effective
and economic public health tools for control of infec-
tious disease [1]. However, vaccine development faces a
number of challenges, such as overcoming the limited
effectiveness of a number of vaccines, the need for fre-
quent vaccine reformulation, as well as a complete lack
of vaccines for some diseases. A central goal of vaccina-
tion is to generate long lasting and broadly protective
immunity against target pathogens, but this goal is ham-
pered by the variability of both the target pathogens and
the human immune system [2]. Current practical solu-
tions to the problem include polyvalent vaccines such as
those being developed for dengue virus [3] or seasonal
vaccine reformulation against influenza [4].
The majority of traditional vaccines provide protection
through neutralizing antibodies and T cells alone rarely
offer protection and prevention of diseases. However,
they participate in reduction, control, and clearance of
intracellular pathogens and have been linked with protec-
tive immunity against a number of viral pathogens [5-8].
The biggest success of immunological bioinformatics is
the development of algorithms for prediction of peptide
binding affinity to the human leukocyte antigen (HLA) -
one of the rate limiting steps in T cell-based immune
response [9]. Although current forms of these algorithms
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are highly accurate [10-12], the output alone is not
enough to inform the selection of epitopes for therapeu-
tic applications. In the conceptual framework for reverse
vaccinology, Rino Rappouli described in silico predictions
of immune epitopes from biological sequence data as a
“naïve approach” when compared with experimental elu-
cidation immunogenic peptides. Many parameters of a
good vaccine target conferring efficient, lasting immunity,
still remain to be considered after prediction of HLA
binding: multiple rate-limiting steps of peptide pre-
processing, confirming in vivo expression, considering
dynamics of expression in different developmental stages
and cellular environments, presence of epitope across
pathogen population, response across host population,
epitope stability over time, and others [13]. Here, we
address the issue of variability by modifying the antigen
selection step with a computational method for selecting
multiple T cell targets from functionally homologous
protein regions.
Traditionally, vaccine targets are selected from con-
served regions in the genome of the pathogen in question,
with the aim of conferring broad and lasting immunity.
The first step is a variability analysis performed by calcu-
lating the frequency of nucleotides or amino acids on each
position in a multiple sequence alignment (MSA) of
homologous genes or proteins [14]. Regions, in which sev-
eral consecutive residues show high conservation (typically
>90% conservation is chosen as the threshold), are then
further analyzed for immunogenic potential either by
computational predictions, experimental testing, or a com-
bination thereof. This systematic exclusion of low fre-
quency variants when using traditional approaches [15-19]
represents a major limiting factor, since immunogenic
potential does not always correlate with the frequency in
the viral population - both rare and common peptides can
be immunogenic and valuable in vaccine constructs aim-
ing for broad coverage [20].
Since the human immune system’s evolution occurs on
a significantly longer time scale than rapidly mutating
pathogens [21], high selective pressure causes them to
alter expression of some immunogenic antigens faster
than the immune system can evolve to keep up with the
changes [22]. The HLA binding affinity of a peptide rela-
tive to its frequency in a viral or malignant cell population
is known as its targeting efficiency (TE). It has been
shown that the TE of peptides varies in different organ-
isms, and in some highly variable viruses it tends to be low
[20]. Regions of high TE comprise peptides that are highly
conserved, most likely owing to the protein’s functional
importance limiting the capacity of a pathogen to alter the
protein while maintaining its fitness [23]. Regions of low
TE comprise one or more peptides, potentially all of high
HLA binding affinity, but each of them will have a low fre-
quency in the pathogen population. For rapidly mutating
viruses, such as RNA viruses [24] the selective pressure
exerted on HLA-binding peptides, means that host
immunity will often, and in some cases preferentially,
target low frequency epitopes [20].
Selecting vaccine targets from protein regions with
conserved HLA binding
We propose a novel method and visualization scheme for
assessing the stability of protein regions for T cell target
discovery, which takes the evolutionary relationship
between HLA and pathogen epitopes into consideration.
This method is based on analyzing columns of suitably
sized sliding windows (from here on termed “blocks”)
from the rows of sequences in an MSA (Figure 1). An
MSA of homologous protein sequences can be performed
using a number of algorithms [25], and blocks of peptides
of a given size (usually 8-11 amino acids long for HLA
class I restricted epitopes and 13-25 amino acids long for
HLA class II restricted T-cell epitopes) are extracted
from each position in the alignment. The number of pep-
tides in each block indicates the diversity of the block, for
which Shannon entropy and consensus frequency can be
calculated as informative metrics [26].
In order to identify potential T cell targets, HLA bind-
ing affinities are predicted for all peptides in all blocks.
Because blocks are extracted from aligned regions of
homologous proteins, it is likely that the peptides within
a given block display high sequence homology and the
majority show similar HLA binding properties even
when sequence variations exist. Similarly, the regions
surrounding a block will be of high homology, thus
increasing the likelihood that peptides from the same
block will be processed and presented on the surface of
target cells in a similar fashion [27].
Blocks of one or more peptides that are all predicted
to bind to the same HLA alleles with similar affinity are
potentially valuable targets for polyvalent vaccine
designs. This allows for simultaneous immunization
with several epitopes - a necessary tactic against highly
Figure 1 Extraction of blocks from MSA. Subdivision of an MSA
into blocks of peptides, l amino acids in length. In this example, l =
9. Block 1 is highlighted in blue. Moving the sliding window to the
right in the MSA in increments of one position will give all blocks
blocks in the MSA.
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mutating viruses in which mutations introducing drug
resistance can occur within a single day [28,29]. We pre-
viously used a rudimentary version of the block conser-
vation analysis for vaccine target discovery in dengue
virus (DENV) [30] and reported a 10-fold larger number
of potential CD8+ vaccine target candidates as compared
to an earlier benchmark study of DENV vaccine target
candidates [31]. We here formalize the approach and
present a software implementation. To further demon-
strate the utility of block conservation, we performed an
analysis of HLA class I epitopes in influenza A H7N9
hemagglutinin (HA). The software is integrated into a




MSAs were performed using MAFFT [32]. When aligning
highly variable protein sequences, such as proteins from
influenza virus, MSAs will invariably contain a high pro-
portion of gaps. Gaps, typically denoted by a dash “-”, are
artifacts of the MSA algorithms and distort the analysis of
peptides in blocks derived from MSAs. We developed and
applied an algorithm that addresses this by removing gaps
and extending the length of the resulting shortened pep-
tides to match the block length. Extensions are made
either upstream or downstream, depending on which
direction yields the best short read alignment with the rest
of the block.
Block conservation
Variability metrics are based on information content cal-
culated as Shannon entropy [26] and conservation is
defined as the frequency of the predominant peptide. In
the block conservation analysis we calculate the informa-
tion content and frequency of all peptides in an MSA of
N homologous proteins, as previously described [30].
Briefly, the peptides at starting position x are here collec-
tively referred to as a “block”, Bx. The peptides in each
block have user-defined length, l, and in each given
block, a number, Wx, of unique peptides exist. Starting
from the first position x = 1 and increasing x in incre-
ments of one across the entire MSA of length L results in
L-l+1 blocks. The block conservation is assessed using
the minimum percentage, yx, of a block at starting posi-
tion x that must be covered by a subset of peptides, Sw,
for a block to be considered conserved. In our analyses of
the influenza A HA protein for class I binders, the fol-
lowing parameters were used: l = 9, yx = 99%.
Data
The data used to exemplify the application of block con-
servation was extracted from FluKB [33]. We used 148
full sequences from influenza A H7N9 for this analysis.
T-cell epitope prediction
HLA class I binding affinities of peptides were predicted
using NetMHC 3.4 [34]. This method was shown to
offer good accuracy relative to other available methods
[10,11]. The default thresholds for binding level affinity
(IC50 < 500 nM for weak binders and IC50 < 50 nM for
strong binders) were used for binding prediction. Pre-
dictions were performed for the following class I alleles:
A*01:01, A*02:01, A*03:01, A*11:01, A*24:02, B*07:02,
B*08:01, B*15:01. These alleles were chosen since pre-
diction algorithms have proven most accurate for these
alleles [12]. For prediction of binding to all known HLA
class I alleles, NetMHCpan 2.4 [35] can be used (Addi-
tional file 1). This algorithm enables prediction of pep-
tide binding to 886 HLA-A alleles, 1412 HLA-B alleles,
and 617 HLA-C alleles, as opposed to NetMHC 3.4,
which only enables prediction for 34 HLA-A alleles, 33
HLA-A alleles, and 10 HLA-C alleles.
Results and discussion
Visualizing block conservation analysis results
Given the large quantity of outputs from the block con-
servation analysis and HLA binding predictions, we
developed visualizations to provide a convenient way of
summarizing results. The conservation of blocks is
visualized using bar plots of the minimum number of
peptides required to fulfill the user-defined coverage
threshold, yx, (Y axis) for each starting position in an
MSA of the protein or proteome in question (X axis).
The predicted binding affinities of peptide blocks to the
user-specified HLA-I or HLA-II alleles are visualized
using a heat map displayed below the conservation
graph, where each column in the heat map corresponds
to the binding affinity of the given position in the MSA,
and each row corresponds to an HLA allele. This
approach to visualization allows simultaneous overview
of predictions of binding to multiple HLA alleles.
Example application: block conservation of HLA class I
binders in influenza A H7N9 HA
We performed the block conservation analysis and predic-
tion of epitopes from an MSA of the HA protein
sequences. We found 29 conserved blocks in which all
peptides were predicted to bind the same HLA (Figure 2).
This compares favorably to traditional conservation analy-
sis (positions where single predicted HLA binder is of at
least 90% frequency) where less than 2% of these poten-
tially immunogenic regions were captured.
To examine the characteristics of peptides in a given
block, a BlockLogo [36] and a Sequence Logo [14] (gen-
erated using WebLogo [37]) were generated to visually
represent conservation and variability of peptides and
individual residues within block 162 of the influenza A
HA protein represents an example of a region with
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conserved HLA binding. The intra-block diversity is
shown in Figure 3, and a closer look at peptide HLA
binding prediction in this block reveals that all peptides,
despite not being highly conserved individually, are pre-
dicted to bind to B*15:01.
Software implementation of method and visualization
scheme
We developed a software implementation of the visuali-
zation scheme, which is freely available at http://met-
hilab.cbs.dtu.dk/blockcons/. To generate a custom visua-
lization, the user must submit an MSA of proteins of
interest (pathogen or tumor proteins), and select analy-
sis parameters as described below (also described in
detail at http://met-hilab.cbs.dtu.dk/blockcons/html/
instructions.php).
First, a block size between 8 and 25 amino acids (corre-
sponding to the lengths of T-cell epitopes) can be
selected. Then, a conservation threshold (the minimum
accumulated frequency of peptides in a block, required
for the block to be considered adequately covered) for
each block can be selected. Most blocks will contain a
large number of very low frequency variants, which can
be filtered from the block if desired. For example, a pep-
tide present only in a small fraction of examined viral
proteins may be considered evolutionarily unstable (one
or a few occurrences isolated in time and geographic
location), and may be exempt from the analysis if desired.
Figure 2 Blocks of conserved HLA binding in a HA MSA. Visualization of the block conservation analysis and HLA class I binding affinity
predictions for 9mer blocks in which at least 99% of the peptides were predicted to bind at least one of the seven HLA I alleles used in this
example. The bars show the number of peptides in a block (Y axis) at a given starting position in the MSA (X axis). The heat map below the bar
shows the percentage of strains in the MSA predicted to bind to each of the HLA alleles predicted for in these examples. The color of each
position in the heat map matrix ranges from blue (0% accumulated conservation by predicted binders in the block for the given allele) to red
(at least 99% of the blocks are predicted to bind to the given allele with a minimum binding affinity of 500 nM).
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For this purpose, a conservation threshold of, for exam-
ple, 99% can be chosen (i.e. filtering out peptides of less
than 1% conservation). Similarly, this threshold acts as an
immunological conservation threshold, i.e. the minimum
accumulated frequency of predicted HLA binders in a
block, in order for the block to be considered adequately
conserved in terms of potential HLA binding.
To efficiently summarize the data, the size of the
visualization can be reduced based on a user-defined
threshold for displaying blocks. The HLA binding con-
servation threshold will filter the output by displaying
only blocks in which the minimum accumulated fre-
quency of HLA binders is above the threshold.
Conclusions
The introduction of computational methodologies to vac-
cinology has enabled a significant step towards reverse
vaccine design. The current paradigm for antigen selec-
tion is based on assembling a number of highly conserved
peptides predicted to bind HLA, to cover diversity of
pathogen and host with the smallest number of peptides.
From a practical point of view, it would be cheaper and
faster to experimentally validate fewer candidates, techni-
cally easier to include fewer peptides in vaccine designs,
and the final epitope pool carries smaller risk of unde-
sired immunodominance. However, from an evolutionary
point of view, some viruses susceptible to treatment are
likely to escape due to high mutation rates. Indeed,
recent experimental efforts have shown that the TE of
highly variable viruses tends to be rather low [20,38,39],
so the inclusion of low-frequency epitopes in vaccines
may decrease immune escape by these viruses.
We have developed a novel method and that inte-
grates conservation analysis and prediction of immuno-
genic potential of peptides within viral antigens for fast
identification of potential cytotoxic T lymphocyte (CTL)
vaccine targets. The results of this analysis have pro-
vided an order of magnitude more potential targets as
compared with traditional approaches. We addressed
the problems of scale and integration of multiple results
by designing a visual representation for rapid identifica-
tion of potential polyvalent vaccine targets. The software
implementation is freely available at http://met-hilab.
cbs.dtu.dk/blockcons/.
Additional material
Additional File 1: Figure S1: Visualization of conservation and
binding predictions of all DENV blocks to all HLA alleles for which
predictions are available. The bars show the minimum number of
peptides in a block (Y axis) at a given starting position in the MSA (X
axis) required to fulfill the user defined coverage threshold, yx. The heat
map below the bar show the percentage of peptides in the block
predicted to bind to each of the HLA alleles predicted for in these
examples. The color of each position in the heat map matrix ranges from
blue (0% accumulated conservation by predicted binders in the block for
the given allele) to red (blocks predicted to bind to the given allele with
a minimum binding affinity of 500 nM represents 99% conservation in
the block). Alleles have been clustered to reflect similarity in binding
properties. Results of clustering are summarized to the right of the
heatmap.
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Human leukocyte antigen; MSA: multiple sequence alignment; TE: Targeting
efficiency.
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